Cargando…

Early differences in dynamic uptake of (68)Ga-PSMA-11 in primary prostate cancer: A test-retest study

INTRODUCTION: Dynamic PET/CT allows visualization of pharmacokinetics over the time, in contrast to static whole body PET/CT. The objective of this study was to assess (68)Ga-PSMA-11 uptake in pathological lesions and benign tissue, within 30 minutes after injection in primary prostate cancer (PCa)...

Descripción completa

Detalles Bibliográficos
Autores principales:	olde Heuvel, J., de Wit-van der Veen, B. J., Sinaasappel, M., Slump, C. H., Stokkel, M. P. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7853454/ https://www.ncbi.nlm.nih.gov/pubmed/33529259 http://dx.doi.org/10.1371/journal.pone.0246394

Ejemplares similares

Day-to-day variability of [(68)Ga]Ga-PSMA-11 accumulation in primary prostate cancer: effects on tracer uptake and visual interpretation
por: olde Heuvel, Judith, et al.
Publicado: (2020)

(68)Ga-PSMA Cerenkov luminescence imaging in primary prostate cancer: first-in-man series
por: olde Heuvel, Judith, et al.
Publicado: (2020)

Performance evaluation of Cerenkov luminescence imaging: a comparison of (68)Ga with (18)F
por: olde Heuvel, J., et al.
Publicado: (2019)

Predicting the effect of different folate doses on [(68)Ga]Ga-PSMA-11 organ and tumor uptake using physiologically based pharmacokinetic modeling
por: Siebinga, Hinke, et al.
Publicado: (2023)

Multicentre quantitative (68)Ga PET/CT performance harmonisation
por: Huizing, Daphne M. V., et al.
Publicado: (2019)

Competition (‘Steal’ Phenomenon) between [(68)Ga]Ga-PSMA-11 Uptake in Prostate Tumor Tissue Versus Healthy Tissue
por: van der Sar, Esmée C. A., et al.
Publicado: (2021)

Mild (68)Ga PSMA-11 Uptake in Incidental Pituitary Adenoma
por: Beyhan, Ediz, et al.
Publicado: (2022)

(44)Sc-PSMA-617 for radiotheragnostics in tandem with (177)Lu-PSMA-617—preclinical investigations in comparison with (68)Ga-PSMA-11 and (68)Ga-PSMA-617
por: Umbricht, Christoph A., et al.
Publicado: (2017)

[(68)Ga]Ga-PSMA-11: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
por: Hennrich, Ute, et al.
Publicado: (2021)

What’s behind (68)Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns
por: Rüschoff, Jan H., et al.
Publicado: (2021)

Automated synthesis and quality control of [(99m)Tc]Tc-PSMA for radioguided surgery (in a [(68)Ga]Ga-PSMA workflow)
por: Aalbersberg, Else A., et al.
Publicado: (2020)

Cost-effectiveness of the implementation of [(68)Ga]Ga-PSMA-11 PET/CT at initial prostate cancer staging
por: van der Sar, Esmée C. A., et al.
Publicado: (2022)

PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and (68)Ga‐PSMA‐11 PET Using Cyclotron‐Produced (68)Ga
por: Thompson, Scott M., et al.
Publicado: (2021)

In vitro and in vivo comparative study of a novel (68)Ga-labeled PSMA-targeted inhibitor and (68)Ga-PSMA-11
por: Chen, Huanyu, et al.
Publicado: (2021)

Cyclotron-based production of (68)Ga, [(68)Ga]GaCl(3), and [(68)Ga]Ga-PSMA-11 from a liquid target
por: Rodnick, Melissa E., et al.
Publicado: (2020)

Multiparametric dynamic whole-body PSMA PET/CT using [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007
por: Dias, André H., et al.
Publicado: (2023)

(68)Ga-PSMA-11 PET/CT versus (68)Ga-PSMA-11 PET/MRI for the detection of biochemically recurrent prostate cancer: a systematic review and meta-analysis
por: Huang, Ruizhe, et al.
Publicado: (2023)

Intra-Individual Comparison of Physiologic [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007 Uptake in Ganglia in Patients with Prostate Cancer: A Retrospective, Monocentric Analysis
por: Novruzov, Emil, et al.
Publicado: (2023)

Radiation dosimetry of [(68)Ga]PSMA-11 in low-risk prostate cancer patients
por: Sandgren, Kristina, et al.
Publicado: (2019)

68Ga-labeled PSMA-11 (68Ga-isoPROtrace-11) synthesized with ready to use kit: normal biodistribution and uptake characteristics of tumour lesions
por: Kurash, Marina Muchnik, et al.
Publicado: (2020)

Comparison of [(18)F]PSMA-1007 with [(68)Ga]Ga-PSMA-11 PET/CT in Restaging of Prostate Cancer Patients with PSA Relapse
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Impact of [(177)Lu]Lu-PSMA-617 Radioligand Therapy on Reference Organ Uptake Assessed by [(68)Ga]Ga-PSMA-11-PET/CT
por: Groener, Daniel, et al.
Publicado: (2023)

Monosodium Glutamate Reduces (68)Ga-PSMA-11 Uptake in Salivary Glands and Kidneys in a Preclinical Prostate Cancer Model
por: Rousseau, Etienne, et al.
Publicado: (2018)

Impact of external cooling with icepacks on (68)Ga-PSMA uptake in salivary glands
por: van Kalmthout, Ludwike W. M., et al.
Publicado: (2018)

Gallium-68 prostate-specific membrane antigen ([(68)Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study
por: Lawhn-Heath, Courtney, et al.
Publicado: (2020)

Primary Staging of Prostate Cancer Patients with [(18)F]PSMA-1007 PET/CT Compared with [(68)Ga]Ga-PSMA-11 PET/CT
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Investigation of the halo-artifact in (68)Ga-PSMA-11-PET/MRI
por: Heußer, Thorsten, et al.
Publicado: (2017)

Baseline [(68)Ga]Ga-PSMA-11 PET/CT before [(177)Lu]Lu-PSMA-617 Radioligand Therapy: Value of PSMA-Uptake Thresholds in Predicting Targetable Lesions
por: Groener, Daniel, et al.
Publicado: (2023)

Research Highlight: (68)Ga-PSMA-11 PET Imaging for Pelvic Nodal Metastasis in Prostate Cancer
por: Fütterer, Jurgen J., et al.
Publicado: (2022)

Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with (68)Ga-PSMA-11 PET/MRI in men with treatment-naïve prostate cancer
por: Ettala, Otto, et al.
Publicado: (2019)

Whole-body uptake classification and prostate cancer staging in (68)Ga-PSMA-11 PET/CT using dual-tracer learning
por: Capobianco, Nicolò, et al.
Publicado: (2021)

What to Trust, PSA or [(68)Ga]Ga-PSMA-11: Learn from Experience
por: Viglialoro, Rita, et al.
Publicado: (2021)

Voxel-based comparison of [(68)Ga]Ga-RM2-PET/CT and [(68)Ga]Ga-PSMA-11-PET/CT with histopathology for diagnosis of primary prostate cancer
por: Fassbender, Thomas Franz, et al.
Publicado: (2020)

A prospective head-to-head comparison of [(68)Ga]Ga-P16-093 and [(68)Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer
por: Wang, Guochang, et al.
Publicado: (2023)

Dual-Time Point [(68)Ga]Ga-PSMA-11 PET/CT Hybrid Imaging for Staging and Restaging of Prostate Cancer
por: Hoffmann, Manuela A., et al.
Publicado: (2020)

Antihormone treatment differentially regulates PSA secretion, PSMA expression and (68)Ga–PSMA uptake in LNCaP cells
por: Mathy, C. S., et al.
Publicado: (2021)

Intraindividual comparison of [(68) Ga]-Ga-PSMA-11 and [(18)F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis
por: Hoberück, Sebastian, et al.
Publicado: (2021)

Detection efficacy of [(89)Zr]Zr-PSMA-617 PET/CT in [(68)Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer
por: Rosar, Florian, et al.
Publicado: (2023)

(68)Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients
por: Zang, Shiming, et al.
Publicado: (2017)

Staging Prostate Cancer with (68)Ga-PSMA-11 PET/CT in the Elderly: Is Preimaging Biopsy Imperative?
por: Kesler, Mikhail, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_o4v19i3esc3vbc9okrtvi3a0o5